Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

Current trends in pharmaceutical treatment of Dry Eye Disease: A review

Dry eye disease (DED), keratoconjunctivitis sicca or dysfunctional tear syndrome, is the most prevalent ophthalmic disease which affects a substantial segment of people worldwide with increasing frequency. It is considered a multifactorial disease of the ocular surface and tear film, characterized by a variation of signs and symptoms. The symptoms range from mild to severe itching, burning, irritation, eye fatigue, and ocular inflammation that may lead to potential damage to the cornea, conjunctiva and even vision loss. Correspondingly, depending on the different manifestations and pathophysiology, the treatment must be tailored specifically to each patient by targeting the specific mechanisms implicated in their disease. Currently, there are several medical products and techniques available or under investigation for the treatment of DED. The present article focused on the pathophysiology of DED, the new diagnostic approach and the recently developed drug delivery systems or devices reducing the progress of the disease and treating the causes.

Attrition und Osmokinetik – Zwei Konzepte zur Pathogenese des Trockenen Auges

Die neuen Erkenntnisse der Pathophysiolgie des Trockenen Auges erkennen das Zusammenspiel von Tränen, Augenoberfläche und Lidoberfläche als eine funktionelle Einheit an. Der Begriff der Benetzungsfähigkeit der Tränen in Abhängigkeit der mikrotektonischen Anatomie der Augenoberfläche relativiert die Anforderungen an Träne und Tränenersatzmittel. Das Model der Attrition, welches die Effekte der friktionsneutralisierenden Kapazität des Tränenfilms, der Reibung und die Bedeutung der Mechanotransduktionskapazität des Epithels zusammenfasst, wird eingeführt und dessen pathophysiologische Bedeutung erläutert. Attrition und Benetzung bestimmen zusammen grundlegende pathophysiologische Vorgänge in der Augenoberfläche wie Aktivierung von Nerven (subjektive Beschwerden) sowie Entzündung und beeinflussen damit die Dynamik der Pathophysiologie, und den Übergang von vorübergehenden Beschwerden zu einer manifesten Erkrankung des Trockenen Auges. Die Betrachtung der Osmolarität als numerischer statischer Grenzwert zur alleinigen Diagnose des Trockenen Auges ist klinisch nicht haltbar. Das neue, dynamische Model der Osmokinetik, zeigt dagegen eine Alternative auf, in der die Tageschwankungen und die Beachtung des durchschnittlichen Osmolaritätsniveaus gröβere Bedeutung gewinnen und damit der eigentlichen pathophysiologischen Bedeutung der Osmolarität gerechter wird.

Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies

Damage to the optic nerve and the death of associated retinal ganglion cells (RGCs) by elevated intraocular pressure (IOP), also known as glaucoma, is responsible for visual impairment and blindness in millions of people worldwide. The ocular hypertension (OHT) and the deleterious mechanical forces it exerts at the back of the eye, at the level of the optic nerve head/optic disc and lamina cribosa, is the only modifiable risk factor associated with glaucoma that can be treated. The elevated IOP occurs due to the inability of accumulated aqueous humor (AQH) to egress from the anterior chamber of the eye due to occlusion of the major outflow pathway, the trabecular meshwork (TM) and Schlemm’s canal (SC). Several different classes of pharmaceutical agents, surgical techniques and implantable devices have been developed to lower and control IOP. First-line drugs to promote AQH outflow via the uveoscleral outflow pathway include FP-receptor prostaglandin (PG) agonists (e.g., latanoprost, travoprost and tafluprost) and a novel non-PG EP2-receptor agonist (omidenepag isopropyl, Eybelis^®). TM/SC outflow enhancing drugs are also effective ocular hypotensive agents (e.g., rho kinase inhibitors like ripasudil and netarsudil; and latanoprostene bunod, a conjugate of a nitric oxide donor and latanoprost). One of the most effective anterior chamber AQH microshunt devices is the Preserflo^® microshunt which can lower IOP down to 10–13 mmHg. Other IOP-lowering drugs and devices on the horizon will be also discussed. Additionally, since elevated IOP is only one of many risk factors for development of glaucomatous optic neuropathy, a treatise of the role of inflammatory neurodegeneration of the optic nerve and retinal ganglion cells and appropriate neuroprotective strategies to mitigate this disease will also be reviewed and discussed.